Discovery Laboratories, Inc. Announces FDA Approval Of SURFAXIN (lucinactant) For Prevention Of Respiratory Distress Syndrome

Discovery Laboratories, Inc. announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS. SURFAXIN is the synthetic, peptide-containing surfactant approved for use in neonatal medicine. Discovery Labs anticipates that SURFAXIN will be commercially available in the United States in late 2012.